John Lazenby, PA
Surgical · McAlester, OKNPI 1336779206
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 29.1% of the total. Reporting peaked in 2021 at $297 and has fallen 65.1% since, to $104 in 2025.
Across 40 payments — averaging $19.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$223
- Stryker$114
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$101
- Pacira Pharmaceuticals Incorporated$70
- Organogenesis Inc.$45
- Gilead$45
- plus $168 from 8 others
What the payments were for
- Food & beverage$765100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 15 | $223 |
| Stryker | 4 | $114 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $101 |
| Pacira Pharmaceuticals Incorporated | 3 | $70 |
| Organogenesis Inc. | 1 | $45 |
| Gilead | 1 | $45 |
| Bioventus LLC | 1 | $36 |
| Intercept Pharmaceuticals, Inc. | 2 | $27 |
| Medacta USA, Inc. | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Vertex | 1 | $19 |
| Dynasplint Systems Inc. | 1 | $16 |
| Evoke Pharma, Inc. | 1 | $15 |
| Bristol Myers Squibb | 1 | $14 |
How this compares
$765 in reported general payments places this provider in the 60th percentile of 94 surgical providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 50 | $982 |
Paid to pharmacies, not to this prescriber.
Other surgical in McAlester
- Kayla HaleOklahoma City$36K
- Randall PapeOklahoma City$25K
- Anne EdmondsTulsa$15K
- Ian GordonOklahoma City$14K
- Isaac EdmondsTulsa$7K
- Camryn CorwinTulsa$5K
- Eduardo GarciaOklahoma City$4K
- Cody ChambersArdmore$4K
- Bryce WrightTulsa$4K
- Jamie TeeterTulsa$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.